The power is in your hands—help prevent
respiratory syncytial virus (RSV) disease
INDICATION
Beyfortus is indicated for the prevention of respiratory syncytial virus (RSV) lower
respiratory tract disease in:
•
Neonates and infants born during or entering their fi rst RSV season.
•
Children up to 24 months of age who remain vulnerable to severe RSV disease
through their second RSV season.
IMPORTANT SAFETY INFORMATION
Contraindication
Beyfortus is contraindicated in infants and children with a history of serious
hypersensitivity reactions, including anaphylaxis, to nirsevimab-alip or to any of the
excipients.
Warnings and Precautions
•
Hypersensitivity Including Anaphylaxis: Serious hypersensitivity reactions,
including anaphylaxis, have been observed with other human IgG1 monoclonal
antibodies. If signs and symptoms of a clinically signifi cant hypersensitivity
reaction or anaphylaxis occur, initiate appropriate medications and/or
supportive therapy.
Discover more
at Beyfortus.com
